Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants

John P. DeVincenzo, Caroline B. Hall, David W. Kimberlin, Pablo J. Sánchez, William J. Rodriguez, Barbara A. Jantausch, Lawrence Corey, Jeffrey Kahn, Janet A. Englund, JoAnn A. Suzich, Frances J. Palmer-Hill, Luis Branco, Syd Johnson, Nita K. Patel, Franco M. Piazza

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.

Original languageEnglish (US)
Pages (from-to)975-978
Number of pages4
JournalJournal of Infectious Diseases
Volume190
Issue number5
DOIs
StatePublished - Sep 1 2004

Fingerprint

Respiratory Syncytial Viruses
Virus Diseases
Palivizumab
Premature Infants
Lung Diseases
Fluorescent Antibody Technique
Epitopes
Heart Diseases
Chronic Disease
Monoclonal Antibodies

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

DeVincenzo, J. P., Hall, C. B., Kimberlin, D. W., Sánchez, P. J., Rodriguez, W. J., Jantausch, B. A., ... Piazza, F. M. (2004). Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants. Journal of Infectious Diseases, 190(5), 975-978. https://doi.org/10.1086/423213

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants. / DeVincenzo, John P.; Hall, Caroline B.; Kimberlin, David W.; Sánchez, Pablo J.; Rodriguez, William J.; Jantausch, Barbara A.; Corey, Lawrence; Kahn, Jeffrey; Englund, Janet A.; Suzich, JoAnn A.; Palmer-Hill, Frances J.; Branco, Luis; Johnson, Syd; Patel, Nita K.; Piazza, Franco M.

In: Journal of Infectious Diseases, Vol. 190, No. 5, 01.09.2004, p. 975-978.

Research output: Contribution to journalArticle

DeVincenzo, JP, Hall, CB, Kimberlin, DW, Sánchez, PJ, Rodriguez, WJ, Jantausch, BA, Corey, L, Kahn, J, Englund, JA, Suzich, JA, Palmer-Hill, FJ, Branco, L, Johnson, S, Patel, NK & Piazza, FM 2004, 'Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants', Journal of Infectious Diseases, vol. 190, no. 5, pp. 975-978. https://doi.org/10.1086/423213
DeVincenzo JP, Hall CB, Kimberlin DW, Sánchez PJ, Rodriguez WJ, Jantausch BA et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants. Journal of Infectious Diseases. 2004 Sep 1;190(5):975-978. https://doi.org/10.1086/423213
DeVincenzo, John P. ; Hall, Caroline B. ; Kimberlin, David W. ; Sánchez, Pablo J. ; Rodriguez, William J. ; Jantausch, Barbara A. ; Corey, Lawrence ; Kahn, Jeffrey ; Englund, Janet A. ; Suzich, JoAnn A. ; Palmer-Hill, Frances J. ; Branco, Luis ; Johnson, Syd ; Patel, Nita K. ; Piazza, Franco M. / Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants. In: Journal of Infectious Diseases. 2004 ; Vol. 190, No. 5. pp. 975-978.
@article{949783d160df47c3b26b842301c9cf4a,
title = "Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants",
abstract = "Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.",
author = "DeVincenzo, {John P.} and Hall, {Caroline B.} and Kimberlin, {David W.} and S{\'a}nchez, {Pablo J.} and Rodriguez, {William J.} and Jantausch, {Barbara A.} and Lawrence Corey and Jeffrey Kahn and Englund, {Janet A.} and Suzich, {JoAnn A.} and Palmer-Hill, {Frances J.} and Luis Branco and Syd Johnson and Patel, {Nita K.} and Piazza, {Franco M.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1086/423213",
language = "English (US)",
volume = "190",
pages = "975--978",
journal = "The Journal of infectious diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants

AU - DeVincenzo, John P.

AU - Hall, Caroline B.

AU - Kimberlin, David W.

AU - Sánchez, Pablo J.

AU - Rodriguez, William J.

AU - Jantausch, Barbara A.

AU - Corey, Lawrence

AU - Kahn, Jeffrey

AU - Englund, Janet A.

AU - Suzich, JoAnn A.

AU - Palmer-Hill, Frances J.

AU - Branco, Luis

AU - Johnson, Syd

AU - Patel, Nita K.

AU - Piazza, Franco M.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.

AB - Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.

UR - http://www.scopus.com/inward/record.url?scp=4344651091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344651091&partnerID=8YFLogxK

U2 - 10.1086/423213

DO - 10.1086/423213

M3 - Article

C2 - 15295704

AN - SCOPUS:4344651091

VL - 190

SP - 975

EP - 978

JO - The Journal of infectious diseases

JF - The Journal of infectious diseases

SN - 0022-1899

IS - 5

ER -